This work validates PRMT5 as a promising therapeutic target for canine lymphoma and supports the continued use of the spontaneously occurring canine lymphoma model for the preclinical development of PRMT5 inhibitors for the treatment of NHL in people. The gene discussed is PRMT5; the disease is non-Hodgkin lymphoma.